A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
NCT ID: NCT00486200
Last Updated: 2017-12-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
695 participants
INTERVENTIONAL
2007-06-21
2008-08-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Oral administration of active comparator
valacyclovir
Oral administration of active comparator.
2
Oral administration of placebo
Placebo
Oral administration of placebo.
3
Dosing regimen 1
ASP2151
Oral administration.
4
Dosing regimen 2
ASP2151
Oral administration.
5
Dosing regimen 3
ASP2151
Oral administration.
6
Dosing regimen 4
ASP2151
Oral administration.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ASP2151
Oral administration.
valacyclovir
Oral administration of active comparator.
Placebo
Oral administration of placebo.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject has experienced 4 or more episodes of genital herpes during the past 12 months
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Astellas Pharma Inc
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Use Central Contact
Role: STUDY_DIRECTOR
Astellas Pharma US, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Birmingham, Alabama, United States
Phoenix, Arizona, United States
Tucson, Arizona, United States
Los Angeles, California, United States
Sacramento, California, United States
San Diego, California, United States
Westlake Village, California, United States
Denver, Colorado, United States
Boynton Beach, Florida, United States
Miami, Florida, United States
Atlanta, Georgia, United States
Indianapolis, Indiana, United States
Madisonville, Kentucky, United States
Baltimore, Maryland, United States
Billings, Montana, United States
Omaha, Nebraska, United States
Albuquerque, New Mexico, United States
Portland, Oregon, United States
Philadelphia, Pennsylvania, United States
Arlington, Texas, United States
Houston, Texas, United States
Houston, Texas, United States
Salt Lake City, Utah, United States
Annandale, Virginia, United States
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Tyring S, Wald A, Zadeikis N, Dhadda S, Takenouchi K, Rorig R. ASP2151 for the treatment of genital herpes: a randomized, double-blind, placebo- and valacyclovir-controlled, dose-finding study. J Infect Dis. 2012 Apr 1;205(7):1100-10. doi: 10.1093/infdis/jis019. Epub 2012 Feb 20.
Related Links
Access external resources that provide additional context or updates about the study.
Link to results on the Astellas Clinical Study Results website.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
15L-CL-101
Identifier Type: -
Identifier Source: org_study_id